Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools

Merkel, O; Hamacher, F; Sifft, E; Kenner, L; Greil, R MOL CANCER THER. 2011; 10(7): 1127-1136.

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Bago-Horvath, Z; Rudas, M; Dubsky, P; Jakesz, R; Singer, CF; Kemmerling, R; Greil, R; Jelen, A; Bohm, G; Jasarevic, Z; Haid, A; Gruber, C; Postlberger, S; Filipits, M; Gnant, M CLIN CANCER RES. 2011; 17(24): 7828-7834.

Complete remission of Waldenström macroglobulinemia with azacitidine and rituximab.

Weiss, L; Melchardt, T; Neureiter, D; Kemmerling, R; Moshir, S; Pleyer, L; Greil, R; Egle, A; J CLIN ONCOL. 2011; 29(24): e696-e698.

Allogeneic bone marrow vs. peripheral blood stem cell transplantation: a long-term retrospective single-center analysis in 329 patients.

Auberger, J; Clausen, J; Kircher, B; Kropshofer, G; Lindner, B; Nachbaur, D; Eur J Haematol. 2011; 87(6): 531-538.

A novel screening system improves genetic correction by internal exon replacement.

Koller, U; Wally, V; Mitchell, LG; Klausegger, A; Murauer, EM; Mayr, E; Gruber, C; Hainzl, S; Hintner, H; Bauer, JW; Nucleic Acids Res. 2011; 39(16): e108

Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.

Wipfler, P; Oppermann, K; Pilz, G; Afazel, S; Haschke-Becher, E; Harrer, A; Huemer, M; Kunz, A; Golaszewski, S; Staffen, W; Ladurner, G; Kraus, J; Mult Scler. 2011; 17(1):16-23

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

Worel, N; Rosskopf, K; Neumeister, P; Kasparu, H; Nachbaur, D; Russ, G; Namberger, K; Witt, V; Schloegl, E; Zojer, N; Linkesch, W; Kalhs, P; Greinix, HT; TRANSFUSION. 2011; 51(5): 968-975.

Sentinel Node Biopsy After Primary Chemotherapy in Breast Cancer: A Note of Caution from Results of ABCSG-14

Tausch, C; Steger, GG; Haid, A; Jakesz, R; Fridrik, MA; Reitsamer, R; Postlberger, S; Lang, A; Gnant, M; Greil, R BREAST J. 2011; 17(3): 230-238.

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Filipits, M; Rudas, M; Jakesz, R; Dubsky, P; Fitzal, F; Singer, CF; Dietze, O; Greil, R; Jelen, A; Sevelda, P; Freibauer, C; Muller, V; Janicke, F; Schmidt, M; Kolbl, H; Rody, A; Kaufmann, M; Schroth, W; Brauch, H; Schwab, M; Fritz, P; Weber, KE; Feder, IS; Hennig, G; Kronenwett, R; Gehrmann, M; Gnant, M CLIN CANCER RES. 2011; 17(18): 6012-6020.

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin“s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Borchmann, P; Haverkamp, H; Diehl, V; Cerny, T; Markova, J; Ho, AD; Eich, HT; Mueller-Hermelink, HK; Kanz, L; Greil, R; Rank, A; Paulus, U; Smardova, L; Huber, C; Dörken, B; Nerl, C; Krause, SW; Mueller, RP; Fuchs, M; Engert, A; J Clin Oncol. 2011; 29(32): 423-442.